This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Natpar
  • /
  • A Open-label Study Investigating the Safety and To...
Clinical trial

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Read time: 2 mins
Last updated:1st Apr 2011
Identifier: NCT01297309

This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.


Study Type: Interventional
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
Estimated Enrollment: 50
Study Start Date: April 2011
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
NPSP558 (titration of 25, 50, 75 or 100 μg)

Category Value
Date last updated at source 2017-02-01
Study type(s) Interventional
Expected enrolment 50
Study start date 2011-04-01
Estimated primary completion date 2018-01-01

View full details